ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
#First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndrome
#ArQule receives Investigational New Drug approval for ARQ 751
BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced a pipeline update for its AKT inhibitors, including ARQ 092 and ARQ 751, both orally available, selective pan-AKT inhibitors.
ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
#First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndrome
#ArQule receives Investigational New Drug approval for ARQ 751
BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced a pipeline update for its AKT inhibitors, including ARQ 092 and ARQ 751, both orally available, selective pan-AKT inhibitors.
http://investors.arqule.com/releasedetail.cfm?ReleaseID=952158